Hyperprolactinemia changes the sulfated glycosaminoglycan amount on the murine uterus during the estrous cycle.
OBJECTIVE
To evaluate the effects of hyperprolactinemia on the sulfated glycosaminoglycans (GAGs) of the murine uterus.


METHODS
Experimental research.


METHODS
University biochemistry laboratory.


METHODS
Eighty female mice were divided into two groups of 40 animals each and treated with 0.2 mL of saline solution (controls, Ctr) and 200 μg of metoclopramide (experimental, HPrl). Treatments lasted for 50 consecutive days. The animals were divided into four subgroups of 10 animals each per treatment (Ctr and HPrl) and sacrificed according to the phase of the estrous cycle. The uterine horns were removed for biochemical analyses, and blood samples were collected for hormone measurements.


METHODS
Induced hyperprolactinemia.


METHODS
To quantify the sulfated GAGs, and PRL and sex steroid levels.


RESULTS
The endometrium during the estrus phase was significantly thicker in the HPrl animals than in the Ctr mice. The levels of chondroitin and dermatan sulfate were significantly increased in the HPrl group than in the Ctr group during all phases except metestrus. The amounts of heparan sulfate were lower during estrus and diestrus and higher in the metestrus phase in HPrl than in Ctr animals. Serum PRL levels were increased whereas the levels of E2 and P were decreased in all phases in the HPrl group than in the Ctr group.


CONCLUSIONS
The hyperprolactinemia changed the amounts of uterine sulfated GAGs. Our data suggest that these changes may not be correlated with ovarian steroid levels.
Department of Gynecology, Faculty of Medicine University of São Paulo, São Paulo, Brazil. Electronic address: celiateixeira2000@yahoo.com.br.
Regina Célia Teixeira
RC
Gomes
Gabriela Carolina Carozi Cristofani
GC
Maioral
Carina
C
Verna
Marisa Teresinha
MT
Patriarca
Helena Bonciani
HB
Nader
Ricardo Santos
RS
Simões
Edmund Chada
EC
Baracat
José Maria
JM
Soares
D000818:Animals; D015415:Biomarkers / Q000097:blood; D002809:Chondroitin Sulfates / Q000378:metabolism; D003871:Dermatan Sulfate / Q000378:metabolism; D004195:Disease Models, Animal; D004958:Estradiol / Q000097:blood; D030762:Estrous Cycle / Q000097:blood / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D006025:Glycosaminoglycans / Q000378:metabolism*; D006497:Heparan Sulfate / Q000378:metabolism; D006966:Hyperprolactinemia / Q000097:blood / Q000378:metabolism* / Q000503:physiopathology; D008787:Metoclopramide / Q000494:pharmacology; D051379:Mice; D011374:Progesterone / Q000097:blood; D013997:Time Factors; D014599:Uterus / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology
D015415:Biomarkers; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004958:Estradiol; D006025:Glycosaminoglycans; D006497:Heparan Sulfate; D008787:Metoclopramide; D011374:Progesterone; C013786:A73025
Estrous cycle; glycosaminoglycans; hyperprolactinemia; mice; uterus